Literature DB >> 24389447

Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

Nir Peled1, Leor Zach, Ori Liran, Maya Ilouze, Paul A Bunn, Fred R Hirsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24389447     DOI： 10.1097/JTO.0000000000000038

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

1.  Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Authors:  Sai-Hong Ignatius Ou; Karen R Sommers; Michele C Azada; Edward B Garon
Journal:  Oncologist       Date:  2015-01-07

Review 2.  The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.

Authors:  Alessia Spagnuolo; Matteo Muto; Fabio Monaco; Giuseppe Colantuoni; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report.

Authors:  Aya Fukuizumi; Akihiko Miyanaga; Masahiro Seike; Yasuhiro Kato; Shinji Nakamichi; Kumi Chubachi; Masaru Matsumoto; Rintaro Noro; Yuji Minegishi; Shinobu Kunugi; Kaoru Kubota; Akihiko Gemma
Journal:  BMC Res Notes       Date:  2015-04-23

4.  Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.

Authors:  Nir Peled; Waleed Kian; Edna Inbar; Iris M Goldstein; Melanie Zemel; Ofer Rotem; Anna B Rozenblum; Hovav Nechushtan; Elizabeth Dudnik; Daniel Levin; Alona Zer; Shoshana Keren-Rosenberg; Shlomit Yust-Katz; Vered Fuchs; Areen A Remilah; Ilan Shelef; Laila C Roisman
Journal:  Neurooncol Adv       Date:  2021-12-27

Review 5.  Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Authors:  Gouji Toyokawa; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 6.  Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis.

Authors:  Rute M S M Pedrosa; Dana A M Mustafa; Joachim G J V Aerts; Johan M Kros
Journal:  Front Oncol       Date:  2018-05-11       Impact factor: 6.244

7.  Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases.

Authors:  Iris M Goldstein; Laila C Roisman; Shoshana Keren-Rosenberg; Julia Dudnik; Hovav Nechushtan; Ilan Shelef; Vered Fuchs; Waleed Kian; Nir Peled
Journal:  Neurooncol Adv       Date:  2020-09-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.